Abstract:
본 발명은 퓨에라리아 속 식물 뿌리의 알콜 추출물을 함유하는 항암용 조성물에 관한 것으로, 항암 효과가 뛰어나며 부작용이 적어 각종 암의 예방과 치료에 유용하게 사용될 수 있다. 또한, 본 발명의 퓨에라리아 속 식물 뿌리의 알콜 추출물은 피부에 안정할 뿐 아니라, 보습효과, 피부 탄력 효과, 잔주름, 기미, 잡티 등의 예방에 효과적이므로, 화장료 조성물로 유용하게 사용될 수 있다.
Abstract:
본 발명은 공역화 리놀레인산(CLA)을 생산할 수 있는 신규한 균주에 관한 것이다. 본 발명의 균주에는 비피도박테리움 브레베( Bifidobacterium breve ) CBG-C2 균주, 비피도박테리움 슈도카르테눌라툼( Bifidobacterium pseudocartenulatum ) CBG-C4 균주 및 엔테로코커스 패시움( Enterococcus faecium ) CBG-C5 균주가 포함된다. 본 발명의 균주는 CLA 생산 능력이 우수하며, CLA를 생성하여 배지로 분비하는 한편 균체 내에 축적할 수 있다. 또한 본 발명의 균주는 위산이나 담즙 등의 산과 항생물질에 대해 강한 내성을 지닌다. 본 발명의 균주를 포함하는 조성물은 수용성 다당류로 이루어진 피복물질 내에 본 발명의 균주와 CLA를 포함하는 캡슐제 형태로 제조되어, 기능성 식품 및 의약품으로 사용될 수 있다.
Abstract:
PURPOSE: Provided are a conjugated linoleic acid(CLA) producing microorganism, a capsulated composition comprising the same microorganism, and the functional food using the same composition, which microorganism has improved conjugated linoleic acid(CLA) producing activity, secretes CLA into the medium and accumulates CLA within the biomass, and has tolerance against acids such as acid in the stomach and bile juice and antibiotics. CONSTITUTION: The CLA producing microorganism which converts linoleic acid(LA) into conjugated linoleic acid(CLA) is provided, wherein the CLA producing microorganism is Enterococcus faecium CBG-C5(KACC 91002). The capsulated composition for prevention and treatment of cancer, arteriosclerosis, diabetes and obeseness comprises the CLA producing microorganism Enterococcus faecium CBG-C5(KACC 91002), wherein the coating material is water-soluble polysaccharides. The functional food containing the capsulated composition is provided, wherein the food is yoghurt, cheese, kimchi and jang(fermented soybean).
Abstract:
PURPOSE: A novel retinoid derivative, its preparation method, a compound used for preparing the derivative, and an anticancer medicine composition containing the derivative are provided, which retinoid derivative shows the excellent anticancer activity and no toxic side effect. CONSTITUTION: The retinoid derivative is represented by the formula I, wherein R¬1 and R¬2 are independent each other and are OH, SH, NH2, COOH, -R(CH2)mCH3, -RCOCO(CH2)mCH3, -RCO(CH2)mCHCH3CH3, or -RCOCH(NCOCH3)CH2CH2CONH2, and R¬3 is H; R¬1 and R¬3 are independent each other and are OH, SH, NH2, COOH, -R(CH2)mCH3, -RCOCO(CH2)mCH3, or -RCOCH(NCOCH3)CH2CH2CONH2, and R¬2 is H; R¬1 is OH, SH, NH2, COOH, -R(CH2)mCH3, R¬2 is H, and R¬3 is H, OH or Cl; R¬3 is OH, SH, NH2, COOH, -R(CH2)mCH3, or -RCOCH(NCOCH3)CH2CH2CONH2, R¬2 is H, and R¬1 is H, OH or Cl; or R¬1, R¬2 and R¬3 are independent each another and are OH, SH, NH2, COOH, -R(CH2)mCH3, or -RCOCH(NCOCH3)CH2CH2CONH2; and R is CH2, O, NH or S, R¬4 is H or an alkyl group of C1-C6, and m is an integer of 0-5.
Abstract:
PURPOSE: A novel method for preparing α-L-aspartyl-L-phenylalanine methyl ester·HCl salt is provided, to reduce the amount of by-products, to allow the by-products to be reused after hydrolysis and to increase the production yield by 20% or more. CONSTITUTION: The method comprises the steps of reacting L-aspartic acid with trimethyl silyl chloride in the presence of an alcohol solvent to esterify the β-COOH selectively to obtain α-L-aspartyl-L-phenylalanine methyl ester·HCl. Preferably the alcohol solvent is selected from the group consisting of methyl alcohol, ethyl alcohol, allyl alcohol and benzyl alcohol. Preferably the method comprises further the steps of protecting an amine group with -CHO, Boc, benzyloxycarbonyl group, or -C(O)OR¬2 (R2 is methyl. ethyl or isobutyl group) by using acetic anhydride and formic acid.